证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 | 编号：20250521 | | --- | | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | ☑其他 2025 年江西辖区上市公司投资者网上集体接待日活动 | | 参与单位名称 | 参与2025年江西辖区上市公司投资者网上集体接待日活动的投资者 | | 时间 | 2025年5月21日 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待 | 董事长彭义兴 | | 人员姓名 | 董事、副总裁、董事会秘书、代理财务总监 刘明 | | | 问：公司今年上半年销售情况如何？公司今年有参加多少展会的准 | | | 备？公司目前在境外的销售是否良好？另外公司在美国几乎没有业务， | | | 是否考虑开拓美国市场？ | | | 答：公司目前生产经营情况正常，公司将在《2025 年半年度报告》 | | | 中披露今年上半年的 ...

Core Viewpoint - Sanxin Medical has achieved significant growth and transformation over the past decade, marking its 10th anniversary since its IPO on the Shenzhen Stock Exchange, with a strategic shift from traditional infusion and injection to blood purification, leading to a substantial increase in revenue from blood purification products [1][2]. Financial Performance - Total revenue increased from 312 million yuan in 2015 to 1.5 billion yuan in 2024, with a compound annual growth rate (CAGR) of 19.07% [2]. - Net profit attributable to shareholders rose from 52 million yuan in 2015 to 227 million yuan in 2024, with a CAGR of 17.85% [2]. - In the last five years, revenue and net profit CAGR reached 15.76% and 29.82%, respectively [2]. Profitability and Returns - The company's gross profit margin reached a record high of 35.33% in 2024 [5]. - By the end of 2024, net assets totaled 1.324 billion yuan, a 4.3-fold increase compared to ten years ago [5]. - Sanxin Medical has distributed cash dividends 11 times since its IPO, totaling 495 million yuan, which is 2.15 times the net amount raised during the IPO; the dividend for 2024 amounted to 156 million yuan, with a payout ratio of 68.77% and an annual dividend yield of 4.17% [5]. Strategic Initiatives - The company is focusing on product innovation and capitalizing on national procurement opportunities while breaking into overseas markets to expand its domestic and international market share [5]. - Sanxin Medical has initiated a global expansion strategy, successfully registering products in countries such as Indonesia, Peru, and Mexico, and is advancing certification processes in Russia and Turkey [5].

文/梧桐晓编 2025年1-3月，沪、深、北三个交易所共受理IPO申报企业只有8家，其中上交所2家，都是科创板，深交所受理1家，申报主板，北交所受理5家。其中申报科创板 IPO的昂瑞微电子报告期累计亏损8.8亿元。申报深交所主板上市的华润新能源为一家设立于中国香港红筹企业，2023年扣非净利润高达82亿元。北交所受理的5 家公司选择的具体上市标准均为《上市规则》第 2.1.3 条第一项：预计市值不低于 2 亿元，最近两年净利润均不低于 1500 万元且加权平均净资产收益率平均不低 于 8%，或者最近一年净利润不低于 2500 万元且加权平均净资产收益率不低于 8%。 8家今年一季度受理的IPO申报企业基本信息 单位：亿元 | 公司简称 | 甲报板块 | 王营业务 | 最近一年 | 最近一年 | 保荐机构 | | --- | --- | --- | --- | --- | --- | | | | | 营收 | 净利润 | | | 昂瑞微电子 | 科创板 | 射频前端芯片、射频SoC芯片及其他模拟芯片的研发设计 | 21.01 | -1.1003 | 中信建投 | | | | 与销售 | | | | | 傲拓科技 ...